Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY

Trial Profile

AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Kidney disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 05 Aug 2015 Planned End Date changed from 31 Dec 2013 to 31 May 2014 as reported by University Hospital Medical Information Network - Japan.
    • 05 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top